Lexeo Therapeutics Inc
NASDAQ:LXEO
Cash Flow Statement
Cash Flow Statement
Lexeo Therapeutics Inc
| Mar-2023 | Jun-2023 | Sep-2023 | Dec-2023 | Mar-2024 | Jun-2024 | Sep-2024 | Dec-2024 | Mar-2025 | Jun-2025 | Sep-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | ||||||||||||
| Net Income |
(65)
|
(64)
|
(84)
|
(66)
|
(69)
|
(77)
|
(87)
|
(98)
|
(109)
|
(114)
|
(105)
|
|
| Depreciation & Amortization |
0
|
0
|
1
|
1
|
1
|
1
|
2
|
1
|
2
|
1
|
1
|
|
| Stock-Based Compensation |
2
|
2
|
3
|
3
|
5
|
7
|
10
|
12
|
14
|
14
|
13
|
|
| Other Non-Cash Items |
3
|
4
|
5
|
5
|
6
|
8
|
10
|
14
|
14
|
11
|
11
|
|
| Cash Interest Paid |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Change in Working Capital |
4
|
(0)
|
4
|
1
|
6
|
5
|
8
|
3
|
5
|
6
|
(14)
|
|
| Cash from Operating Activities |
(58)
N/A
|
(60)
-4%
|
(74)
-23%
|
(59)
+20%
|
(56)
+6%
|
(63)
-12%
|
(67)
-6%
|
(81)
-21%
|
(88)
-8%
|
(95)
-8%
|
(107)
-12%
|
|
| Investing Cash Flow | ||||||||||||
| Capital Expenditures |
(1)
|
(1)
|
(1)
|
(0)
|
(0)
|
(1)
|
(1)
|
(0)
|
0
|
(0)
|
(0)
|
|
| Other Items |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
(94)
|
(78)
|
(117)
|
(82)
|
|
| Cash from Investing Activities |
(1)
N/A
|
(1)
+25%
|
(1)
-9%
|
(0)
+73%
|
(0)
-115%
|
(1)
-51%
|
(1)
-6%
|
(94)
-16 492%
|
(78)
+17%
|
(117)
-50%
|
(82)
+30%
|
|
| Financing Cash Flow | ||||||||||||
| Net Issuance of Common Stock |
0
|
0
|
0
|
0
|
89
|
89
|
89
|
89
|
0
|
80
|
80
|
|
| Net Issuance of Debt |
(0)
|
(0)
|
4
|
4
|
4
|
4
|
(0)
|
(0)
|
(0)
|
(1)
|
(0)
|
|
| Other |
0
|
0
|
(0)
|
100
|
0
|
0
|
0
|
0
|
0
|
(7)
|
(7)
|
|
| Cash from Financing Activities |
(0)
N/A
|
(0)
-82%
|
4
N/A
|
104
+2 783%
|
193
+86%
|
193
+0%
|
189
-2%
|
89
-53%
|
(0)
N/A
|
73
N/A
|
73
+0%
|
|
| Change in Cash | ||||||||||||
| Net Change in Cash |
(59)
N/A
|
(61)
-4%
|
(71)
-17%
|
44
N/A
|
136
+209%
|
130
-5%
|
122
-6%
|
(86)
N/A
|
(166)
-92%
|
(140)
+16%
|
(116)
+17%
|
|
| Free Cash Flow | ||||||||||||
| Free Cash Flow |
(59)
N/A
|
(61)
-3%
|
(75)
-23%
|
(60)
+20%
|
(56)
+5%
|
(63)
-12%
|
(67)
-6%
|
(82)
-21%
|
(88)
-8%
|
(95)
-8%
|
(107)
-13%
|
|